The Public Repository of Xenografts enables discovery and randomized phase II-like trials in mice

More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease

Structural investigations of N-methylformamide-water mixtures at various concentrations

Structural investigations of N-methylformamide-water mixtures (NMF-water) are performed at room temperature and atmospheric pressure for two water molar fractions x w = 0.66 and x w = 0.75 . This paper extends our recent study on the equimolar system. H-bond networks are preferentially formed between NMF and water molecules. Among a large variety of DFT optimized models, X-ray scattering data shows that the local order of each mixture is better described by a tetramer where one NMF molecule is connected to three water molecules. No self-association is observed in the considered systems. The effect of hydration is compared to the temperature and pressure effects in some hydrogen-bonded liquids

The public repository of xenografts enables discovery and randomized phase II-like trials in mice.

More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease